SoFi Technologies, a financial services company, is gaining traction as an online bank with 12.6 million customers, a 35% year-over-year increase. With a digital-first approach and cross-selling strategy, SoFi aims to capture more market share, despite criticisms for relying heavily on personal loans. Its future looks promising as it continues to evolve and grow.

Summit Therapeutics, a biotech company, is developing ivonescimab, a potential cancer therapy that outperformed Merck’s Keytruda in a phase 3 clinical trial. With ivonescimab already approved in China and potential for $53 billion in annual sales, Summit could become a prominent player in the oncology market. Despite risks, the company has exciting growth potential.

Read more at Yahoo Finance: 2 Monster Stocks in the Making to Buy and Hold